Gary W. Pace, Ph.D., Co-Founder and Chairman of the Board

Dr. Pace is a co-founder, director, and consultant to QRxPharma (ASX-listed), a clinical-stage specialty pharmaceutical company listed on the ASX, and he was formerly the chairman and chief executive officer of a predecessor company to QRxPharma. In addition to Sova Pharmaceuticals, he serves as a Director of ResMed, a NASDAQ and ASX-listed company which is a leading developer, manufacturer and marketer of products for the screening, treatment and long-term management of sleep-disordered breathing (SDB) and other respiratory disorders, and Transition Therapeutics, a NASDAQ and TSX-listed company developing new therapies. From 1995 to 2001, Dr. Pace was President and CEO of RTP Pharma, a developer of nano-articulate technology. From 2000 to 2002, Dr. Pace was Chairman and CEO of Waratah Pharmaceuticals Inc., a spin-off company from RTP Pharma. From 1993 to 1994, Dr. Pace was the founding President and Chief Executive Officer of Transcend Therapeutics Inc. (formerly Free Radical Sciences Inc.), a biopharmaceutical company. From 1989 to 1993, he was Senior Vice President of Clintec International, Inc., a Baxter/Nestle joint venture and manufacturer of clinical nutritional products. Dr. Pace holds a B.Sc. with honors from the University of New South Wales and a Ph.D. from MIT.

Jay Lichter, Ph.D., Director

Dr. Lichter currently serves as the company’s president and CEO. Dr. Lichter, a biotechnology and pharmaceutical business executive, has over 20 years experience in management, scientific research and business development. Dr. Lichter has participated in licensing and M&A deals valued in excess of $1 billion. He is currently a managing director at Avalon Ventures and in that capacity is on the board of directors of Afraxis, Otonomy, Carolus, Zacharon, Incode and Akesis. He is an observer at Syndax board meetings. Until November 2008, Dr. Lichter served as president and CEO of Akesis Pharmaceuticals, a developer of patent protected diabetes drugs. He remains on the board of directors as executive chairman. In 2004, Dr. Lichter co-founded and served as vice president of operations at Sytera, Inc., a company that was acquired by Sirion Therapeutics, Inc. in July 2006.

Dr. Lichter has co-founded a number of other biotechnology companies, including Sequana Therapeutics, a genomics-base drug discovery company, and Xenopharm, a drug safety company. Dr. Lichter led negotiations in the development and management of collaborations with numerous pharmaceutical and biotechnology companies across many therapeutic areas. In 2000, Dr. Lichter co-founded and was CEO of Xenopharm, a drug safety company, where he drove the development of the company and its ultimate acquisition by Deltagen. He served in management positions at Sequenom, Pfizer and Genset. Dr. Lichter held postdoctoral positions at DuPont Merck Pharmaceutical Co. and Yale University. He received both his Ph.D. and B.S. at University of Illinois.

Court R. Turner, Director

Court R. Turner, J.D. joined Avalon Ventures as an Advisor in January 2008, focusing on the formation and strategic operations of the Avalon VIII portfolio companies. Within that role, Mr. Turner is the President, CEO and Director of Carolus Therapeutics, Inc. and the Chief Operating Officer of Afraxis, Inc., Zacharon Pharmaceuticals, Inc., Avelas Biosciences, Inc. and Otonomy, Inc. Prior to joining the Avalon team, Mr. Turner spent over a decade of his career within companies in the San Diego biotechnology community. Starting in 1997, Mr. Turner joined Aurora Biosciences Corporation (acquired by Vertex Pharmaceuticals in 2001) in its Legal and Strategic Alliances departments focused on technology licensing, business development and a myriad of corporate legal matters facing a public company, including SEC filings and M&A transactions. In June 2002, Mr. Turner joined Kalypsys, Inc. a then start-up small molecule drug discovery company. During his tenure at Kalypsys, the company grew from 15 to over 125 employees with an impressive product pipeline and three rounds of financing totaling over $170M. Mr. Turner was a member of the Kalypsys Executive Management Team. Mr. Turner received a Bachelor’s Degree from San Diego State University and a Juris Doctor degree from the University of San Diego School of Law.

Sanford J. Madigan, PhD, Director

Dr. Madigan has over 16 years of industry experience and has been instrumental in developing companies' infrastructure, establishing strategic direction, licensing founding and value-added technologies, negotiating strategic partnerships and corporate acquisitions. Dr. Madigan most recently served as a co-founder and Chief Executive Officer of Strategic Enzyme Applications (SEA), a San Diego-based clean technology company that was established, in part, as a strategic relationship with Monsanto. Prior to founding SEA, Dr. Madigan served in various venture-backed biotechnology companies; participating as a founder and/or senior manager in BioVerdant, Nereus Pharmaceuticals, Ambit, Xenopharm (acquired by Deltagen), X-Ceptor (acquired by Exelixis) and SIBIA Neurosciences (acquired by Merck).

Dr. Madigan received his B.S. in Biochemistry and a Ph.D. in Genetics from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research. He performed his post-doctoral training at The Salk Institute for Biological Studies in La Jolla, California.